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Multi-ethnic GWAS and meta-analysis of sleep quality identify MPP6 as a novel gene that 
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Poor sleep quality can have harmful health consequences. Although many aspects of sleep are 
heritable, the understandings of genetic factors involved in its physiology remain limited. 
Here, we performed a genome-wide association study (GWAS) using the Pittsburgh Sleep 
Quality Index (PSQI) in a multi-ethnic discovery cohort (n=2,868) and found two novel 
genome-wide loci on chromosomes 2 and 7 associated with global sleep quality. A meta-
analysis in 12 independent cohorts (100,000 individuals) replicated the association on 
chromosome 7 between NPY and MPP6. While NPY is an important sleep gene, we tested for 
an independent functional role of MPP6. Expression data showed an association of this locus 
with both NPY and MPP6 mRNA levels in brain tissues. Moreover, knockdown of an 
orthologue of MPP6 in Drosophila melanogaster sleep center neurons resulted in decreased 
sleep duration. With convergent evidence, we describe a new locus impacting human 
variability in sleep quality through known NPY and novel MPP6 sleep genes. 
































Statement of significance: Although many aspects of sleep are heritable, the genetic 
architecture of sleep quality remains poorly understood. Here, we conduct a genome-wide 
association study using the Pittsburgh Sleep Quality Index (PSQI) in a multi-ethnic discovery 
cohort. We discovered and replicated a locus on chromosome 7 between NPY and MPP6 
with polymorphisms associated with poor sleep quality. Expression data suggests a higher 
expression of NPY and MPP6 in the brain. NPY, which codes for neuropeptide Y, has been 
found to promote sleep in humans and was identified as an important candidate gene in sleep 
regulation in Drosophila melanogaster. We tested the functional role of MPP6 in lateral 


































Sleep is essential for brain homeostasis and optimal functioning [1]. Poor sleep has 
been shown to have a negative impact on multiple biological processes and can have harmful 
health consequences [2]. There is an intrinsic consequence to poor sleep in the risk of disease; 
for instance, circadian disruption in prolonged night shift workers increases risk of mortality 
from heart disease and cancers [3]. An overwhelming majority of chronic pain patients also 
suffer from poor sleep. The complaints of poor sleep and pain usually co-occur and lead to 
deteriorating quality of life [4]. Furthermore, poor sleep is associated with major depressive 
disorders and increased anxiety [5]. The term poor sleep encompasses a wide range of sleep 
disorders that can include, but are not limited to, insomnia, sleep related breathing disorders, 
circadian rhythm disorders and sleep quality disturbances. Sleep quality is a complex 
phenotype that is defined as a construct of sleep duration, sleep latency, number of arousals 
during sleep and sleep restfulness [6,7]. Laboratory sleep assessment is difficult and costly, 
but validated questionnaires like the Pittsburgh Sleep Quality Index (PSQI) help capture sleep 
quality in healthy and clinical populations [6]. Self-perceived poor sleep quality can be 
difficult to assess. The PSQI captures various components that can potentially affect sleep 
quality such as sleep latency, sleep duration, and sleep efficiency. The content of PSQI has 
been validated against measures taken from polysomnography and covers multiple aspects 
relevant to the sleep quality construct [7]. Although many aspects of sleep are heritable 
(genetic factors explaining an estimated 17-45% of phenotypic variance), the understanding 
of genetics involved in its physiology remains limited [8].  
Genetic factors have previously been shown to influence multiple sleep traits like 
circadian rhythms, sleep duration, sleep latency, sleep apnea, and restless leg syndrome [8-
14]. For instance, MEIS1 has been repeatedly associated with restless leg syndrome, whether 































and was replicated in independent cohorts [17]. Recently, genome-wide association studies 
(GWAS) in large datasets on self-reported insomnia and excessive daytime sleeping also 
identified MEIS1 and PAX8  genes, but with further analyses it became clear that the 
observed signal was likely to be driven by another sleep disorder, namely, restless leg 
syndrome [9,18]. Overall, we are at the beginning of our understanding of the genotypic 
architecture of sleep phenotypes, and there is an unmet need to perform standardized GWAS 
analysis of sleep using validated methodology. Based on the overall heritability of sleep in 
human populations, we would predict small effects from multiple genetic variants. Despite 
substantial evidence for the heritability of sleep quality using the PSQI (37%) [19,20], to 
date, no GWAS has been reported using this tool.   
In order to identify genetic factors implicated in sleep quality, here we present results 
of GWAS using the PSQI among U.S. adults in the Orofacial Pain: Prospective Evaluation 
and Risk Assessment (OPPERA) cohort [21]. Genome-wide significant loci were then carried 
forward for replication across twelve independent cohorts, combining more than 100,000 
individuals. Finally, we performed functional validation of a replicated locus through analysis 
of expression and by monitoring behavioral sleep patterns in transgenic Drosophila 
melanogaster. Together, our systematic genetic analysis of sleep has identified a novel 
conserved sleep locus, and these data help provide a better understanding of the underlying 


































Orofacial Pain Prospective Evaluation and Risk Assessment (OPPERA) 
 Study participants were selected from the OPPERA study, described in detail 
elsewhere [22]. In brief, the OPPERA cohort is a large population-based study designed to 
identify the psychological and physiological risk factors, clinical characteristics, and 
associated genetic mechanisms that influence the development of temporomandibular 
disorders (TMD) and related phenotypes. Individuals aged 18 to 44 years were recruited from 
four demographically diverse US locations (Buffalo, New York; Gainesville, Florida; 
Baltimore, MD; Chapel Hill, North Carolina). Over 200 pain phenotypes and pain related 
comorbidities were collected within this study. For the current analysis, the phenotype of 
interest is the global score of the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a 19-
item standardized validated instrument that assesses subject sleep quality over the last month 
[6]. Global score is derived from the sum of seven sub-components, namely subjective sleep 
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of 
sleep medication and daytime sleepiness. PSQI global score ranges from 0 to 21, where lower 
scores denote good sleep quality and higher scores denote poor sleep quality. Other sleep 
phenotypes, such as insomnia and restless leg syndrome were not assessed in OPPERA. 
Ethics statement 
All OPPERA participants provided informed, signed consent for all study procedures. 
The OPPERA study was approved by institutional review boards at each of the four study 
sites (Buffalo, New York; Gainesville, Florida; Baltimore, MD; Chapel Hill, North Carolina) 































Genotyping, quality control and imputation 
DNA samples were extracted from whole blood following purification using a 
Qiagen™ Extraction Kit. A total of 3,161 samples were genotyped for discovery using the 
Illumina HumanOmni2.5Exome-8v1A array (Illumina, Inc., San Diego, CA) at the Center for 
Inherited Disease Research (Johns Hopkins University, Baltimore, MD); from those, there 
were 2,150 were healthy controls and 1,011 chronic TMD cases. Genetic data cleaning was 
done by the Genetics Coordinating Center at the University of Washington following their 
established pipeline [23]. Batch effects were assessed by comparing missing call rate and chi-
square test for allelic frequency between genotyping batches. Sample identity and sample 
quality analyses included checks for missing call rate, chromosomal anomalies, cryptic 
relatedness, autosomal heterozygosity outliers, gender mismatch, and genetic ancestry. The 
median call rate was 99.9%. Cryptic relatedness was calculated using kinship coefficient with 
the R package SNPRelate. Samples were excluded if there was a discrepancy between 
annotated and genetic sex, the presence of chromosomal abnormalities and higher than 
second degree relatedness (19 parent-offspring pairs, 8 full siblings, and 11 second-degree 
relatives). With these criteria, 57 subjects were excluded for a total of 3,104 samples that 
passed QC. Upon merging with available PSQI scores, a total of 2,868 individuals (1,092 
males and 1,776 females) were retained for the analysis.  
Consistency of genotyping calls was assessed using 68 duplicates of study samples 
and 66 stock samples from HapMap reference subjects. SNP quality checks included 
assessments of missing call rate, duplicate discordance, and Mendelian errors. Because of the 
mixed population structure of the OPPERA cohort, Hardy-Weinberg equilibrium (HWE) was 
tested in homogenous European- and African-ancestry groups separately.  
Cleaned genotypes were then imputed to the 1000 Genomes Project phase 3 reference 































for imputation.  The IMPUTE2 algorithm was selected because it was recommended for use 
in a genetically diverse study sample using a worldwide reference panel. The IMPUTE2 
algorithm uses a “k_hap” value to specify which number of reference haplotypes should be 
used to impute each study sample. The implementation of this parameter is one of the ways 
imputation with a worldwide reference panel is made computationally feasible: i.e., by 
choosing a subset of reference haplotypes to impute each study sample based on perceived 
genetic similarity [27]. The default k_hap value is 500; however, higher values are 
recommended when imputing into admixed populations. Thus for this project we set k_hap to 
2,000. Following SNP QC and imputation, 35 million high-quality SNPs were retained for 
the analysis.  
Power Calculation 
We used the method described in [28] that allows estimating the expected proportion 
of false positives (expected False Discovery Rate, or "expected FDR") among a specified 
number of the smallest P-values, U. The expected number of true positives among U top-
scoring SNPs is given by (1-eFDR)*U. We set U=10, N=2,868, the SNP frequency equal to 
0.15, (the minimum frequency used in the present study for association testing was 0.05), and 
varied the assumed actual number of true positives among about 1.8 million tested SNPs as 
M = (10, 50, 100, 250, 500). To relate the effect size for the continuous standardized outcome 
to a commonly used measure for binary outcomes, the odds ratio, we took these effect sizes 
to correspond to three different values of the odds ratio, 1.2, 1.25, and 1.3. These values give 

































PLINK v.1.90 software was used for genome-wide association analysis under an 
additive model of inheritance [29]. Global PSQI scores were used as a dependent variable in 
a linear regression model. Covariates included in the equation were age, gender, dummy-
coded recruitment sites, 3 principal components to account for population stratification, and 
TMD case status to account for recruitment bias. The three principal components were used 
as they account for the majority of the variance (Supplementary Figure 1). Furthermore, we 
also repeat the analysis using five principle components to further increase stringency of a 
control for population stratification.  Genome-wide statistical significance threshold was set 
at P < 5x10
-8
.  
In addition to the analysis in the full cohort, we also performed a stratified analysis by 
sex and by genetically defined race to account for multi-ancestry. For the race stratified 
analysis, one principle component generated using each race separately was used in the 
model, along with age, gender, dummy-coded recruitment sites and TMD case status. 
Manhattan and quantile-quantile (Q-Q) plots were generated using the R-package qqman 
[30]. Heritability of PSQI global score was computed using GCTA [31]. A conditional 
analysis was performed by adjusting for the other SNP that passed genome-wide significance 
by using its minor allelic count as a co-variable in the linear regression model. 
Expression Quantitative trait loci (eQTL) analysis 
Gene expression was explored using publicly available eQTL online resources. The 
BRAINEAC database [32] which contains gene expression data across ten brain regions 
(cerebellar cortex, frontal cortex, hippocampus, medulla, occipital cortex, putamen, 
substantia nigra, temporal cortex, thalamus and white matter) was used to identify eQTL with 































simply averaging expression values across all ten brain regions. In addition to BRAINEAC, 
the GTEx portal version 6 [33] was used in twelve selected brain tissues (amygdala, anterior 
cingulate cortex, caudate, cerebellar hemisphere, cerebellum, cortex, frontal cortex, 
hippocampus, hypothalamus, nucleus accumbens, putamen and substantia nigra). 
GO enrichment pathway analysis in biological process   
SNPs were assigned to genes based on distance. For cis-effects, we considered 
distances between the SNP and the gene locus up to 10,000 nucleotides, on both positive and 
negative genomic DNA strands. Analyses were performed using the Gene Ontology (GO) 
biological processes pathways definitions (file retrieved May 24th, 2016 [34]). To generate a 
P-value for each pathway, we collected all SNP P-values in cis for all genes pertaining to the 
pathway. We compared the distribution of PSQI GWAS P-values among SNPs belonging to 
the pathway, with the distribution of P-values for SNPs not belonging to the pathway. 
Comparisons were made with the Kolmogorov-Smirnov test using the ks.test function 
implemented in R version 3.6.0. The test was performed in a 1-sided fashion, because we 
searched for pathways enriched with SNPs of lower P-values. A total of 1,133 pathways were 
inspected for enrichment. Adjustment for multiple testing was performed using Bonferroni 
correction. 
Data Availability 
Study data have been deposited and made publicly available at the Database of 
































Replication cohorts’ description 
UK Biobank 
The UK biobank is a prospective study that includes more than 500,000 people living 
in the United Kingdom [35]. In total, over 9.2 million invitations to participate in the study 
were sent, from which 503,325 individuals were recruited between 2006-2010. Participants 
were part of the National Health Service registry, aged between 40-69 years and living less 
than 25 miles from a study center. Recruited study participants gave informed consent and 
completed questionnaires; underwent a range of physical measures; and blood, urine, and 
saliva were collected for genetic data. Samples were genotyped on the UK BiLEVE array 
(~50,000 samples) and the UK Biobank Axiom array (~450,000 samples). Analysis was 
performed on the interim release of genotype data of 152,000 samples. Arrays contain around 
800,000 markers. Following standard QC described elsewhere 
(http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155580), SNPs were imputed for a total of 
73,355,667 SNPs after phasing the autosomes using a modified version of the SHAPEIT3 
program modified to allow for very large sample sizes. Imputation was then carried out using 
IMPUTE3 according to UK biobank standard described elsewhere 
(http://www.ukbiobank.ac.uk/wpcontent/uploads/2014/04/imputation_documentation_May20
15.pdf). Sleep quality was assessed using a self-reported question: “Do you have trouble 
falling asleep at night or do you wake up in the middle of the night?” with four possible 
answers: “never/rarely”, “sometimes”, “usually”, or “prefer not to answer”. This phenotype 
was selected because it is a proxy to the global PSQI score with sensitivity of 0.94, specificity 
of 0.89 and ROC AUC of 0.947 [12]. The phenotype was dichotomized by using only 
“usually” as cases and “never/rarely” as controls. Association testing was performed using 































principal components (PC) to account for population stratification were used as covariates. 
The current study was conducted under UK biobank application number 20802. 
Hispanic Community Health Study /Study of Latinos (HCHS/SOL) 
HCHS/SOL is a longitudinal multicenter cohort study of the Hispanic/Latino 
community in the United States with initial visits between 2008 and 2011. Participants were 
recruited in a two-stage sampling scheme of individuals from the Bronx, NY; Chicago, IL; 
Miami, FL; and San Diego, CA for a total of 16,415 individuals enrolled [36]. Of these, 
12,803 individuals consented to participate in genetic studies. In the current analysis, 
n=10,610 individuals participated after applying exclusion criteria. Genotyping was 
performed with an Illumina custom array (15041502 B3), which consists of the Illumina 
Omni 2.5 M array (HumanOmni2.5-8v1-1) plus approximately 150k custom SNPs. Genome-
wide imputation was carried out using the 1000 Genomes Project phase 1 reference panel, 
SHAPEIT2, and IMPUTE2 software. The quantitative phenotypic outcome is the WHIIRS 
(Women’s Health Initiative Insomnia Rating Scale), which is derived from form code SLE – 
HCHS/SOL Sleep questionnaire:  
WHIIRS = SLEA4 + SLEA5 + SLEA6 + SLEA7 + SLEA11 – 4 
where SLE4 is “Did you have trouble falling asleep?”; SLE5 is “Did you wake up several 
times at night?”’ SLE6 is “Did you wake up earlier than you planned to?”; SLE7 is Did you 
have trouble getting back to sleep after you woke up too early?” with possible answers being 
“No, not in the past 4 weeks”, “Yes, less than once a week”, “Yes, 1 or 2 times a week”, 
“Yes, 3 or 4 times a week” and “Yes, 5 or more times a week”. SLEA11 asks “Overall, was 
your typical night’s sleep during the past 4 weeks" with possible answers “Very sound or 































High WHIIRS scores represent poor sleep quality. For this analysis, WHIIRS score 
was dichotomized with disturbed sleep defined as WHIIRS score of at least 9. Sex, age, 
recruitment center, 5 PC, and TMD status were used as covariates in the analysis. Subjects 
were excluded from the analysis if they presented any other sleep disorder, such as restless 
leg syndrome, narcolepsy, or sleep apnea, or if they were taking sleeping pills for the past 4 
weeks. 
EA-CRASH 
This is a prospective cohort study of adults of European ancestry (EA) who presented 
to an emergency department (ED) following a motor vehicle collision (MVC) [37]. Patients 
were enrolled at 9 study sites across Eastern USA. From a total of 10,629 patients screened, 
1,416 were eligible, 969 consented to study participation, and 948 were enrolled. Data and 
blood samples were collected at the initial emergency department visit, and follow-up data 
was collected at 6 week, 6 month and 1 year assessments. Sleep was assessed using the 
question: “Prior to the accident, in the past month, please rate your insomnia or difficulty 
sleeping” with possible answers coded using a 0-10 scale were 0 denotes “no problems” and 
10 denotes “major problems” with sleep. DNA was extracted from PAXgene blood DNA 
tubes and SNPs were genotyped using Sequenom technology. Due to the low frequency of 
discovery SNPs in EA, minor allele frequency of rs11976703, rs73284230 and rs60869707 
was 1%, 0.1% and 6% respectively. Moreover, genotyping rate of rs73284230 was 92.2%, 
which is lower than the accepted threshold of 95%. The regression analysis included age and 
gender as covariates in the model. 
AA-CRASH 
The African American (AA) CRASH study (n=915) is a sister study of EA CRASH. 































of AA individuals ≥ 18 and ≤ 65 years of age who presented within 24 hours of MVC to one 
of eleven EDs in six states/districts (Michigan, Pennsylvania, Florida, Alabama, 
Massachusetts, and Washington D.C.). The full details of this study have been described 
previously [38]. DNA was collected in the ED using PAXgene DNA tubes. Sleep quality in 
the month prior to MVC was assessed with the same question as in the EA CRASH study 
(above). Following DNA purification (PAXgene blood DNA kit, QIAGEN), genotyping 
using the Infinium Multi-Ethnic Global (MEG) Array (Illumina) was performed.  DNA from 
an individual with known genotype (NA19819, 1000 genomes) and two repeat samples were 
included in each genotyping batch (96 samples) to ensure genotypic accuracy and reliability. 
SNPs rs11976703, rs73284230 and rs60869707 were not included in the MEGA array and 
were thus imputed using available genotyping data. Following, stringent QC and accounts of 
relatedness, the regression analysis included age, gender, and study site as covariates in the 
model. 
The Finnish BrePainGen cohort 
The BrePainGen cohort consists of 1000 Finnish women (aged 18-75 years) who had 
unilateral non-metastasized breast cancer and received surgery at the Breast Surgery Unit, 
Helsinki University Hospital, between August 2006 and December 2010. The day before 
surgery, following informed consent acquisition, medical and medication demographic 
history was taken and background data collected. Patients also underwent experimental cold 
and heat pain tests and answered psychological questionnaires that included questions about 
insomnia. This prospective study cohort has been described in detail earlier [39]. Genotyping 
was done at the Wellcome Trust Sanger Institute (Hinxton, UK) using the Human 
OmniExpress Illumina BeadChip (Illumina, Inc., San Diego, CA, USA). After stringent 
sample quality control procedures, a total of 926 samples passed QC. An MDS plots (12 































homogeneous population. SNPs were filtered based on minor allele frequency (MAF>0.005), 
Hardy-Weinberg equilibrium (HWE p>1x10
-6
) and success rate (>0.97). Insomnia data was 
available for 823 participants. The sub-sample used in this study consists of the 757 
individuals with both genotype and insomnia questionnaire data. The patients who stated that 
they never have insomnia were considered as unaffected (n=399) and those who said that 
they have insomnia at least once a week (n=237) or every night (n=121) were considered 
affected. during which also MDS.  
Post-mastectomy pain syndrome cohort 
This cohort (N =1200) was recruited from the Comprehensive Breast Cancer 
Program’s registry of breast cancer patients undergoing total or partial mastectomy at Magee 
Women’s Hospital of University of Pittsburgh Medical Center. University of Pittsburgh 
Institutional Review Board approval was obtained prior to all data collection, and all patients 
gave informed consent before participation in the study. The majority were postmenopausal. 
Ethnic group was primarily white/Caucasian.  The percentage of women of ethnic groups 
other than white/Caucasian in the study was limited, making an assessment of racial/ethnic 
differences inappropriate. Patients completed study questionnaires a mean of 38.3 ± 35.4 
months (range, 2 months–10 years) after surgery. Full cohort description was reported 
elsewhere [40]. Sleep disturbance was assessed using a short-form instrument from the 
National Institutes of Health roadmap initiative, Patient Reported Outcome Measurement 
Information System (PROMIS) [41]. Genotyping was done using the UK Biobank Axiom 
platform on samples derived from lymph node tissue, blood or saliva. Genotyping was done 
using the UK Biobank Axiom platform on samples derived from lymph node tissue, blood or 
saliva at the Genome center at McGill University. Following QC and imputation, a total of 
665 samples were used in the replication. Age and 3 principal components were used in the 































Complex Persistent Pain Conditions  
The Complex Persistent Pain Conditions (CPPC): Unique and Shared Pathways of 
Vulnerability study included 745 participants enrolled in a case control study of overlapping 
pain conditions conducted at UNC Chapel Hill. Subjects were aged 18-64, and included both 
sexes (86% female) and major ethnic and racial groups (68% non-Hispanic white). All 
subjects had at least one of four index CPPCs (episodic migraine, irritable bowel syndrome, 
fibromyalgia, or vulvar vestibulitis), or were otherwise healthy controls with none of these 
conditions. Sleep quality was assessed using the PSQI. DNA from all subjects was genotyped 
using the Axiom Precision Medicine Research Array by Genome center at McGill University. 
PSQI was used as a dependant variable in a linear regression model with age, gender, 3 PCs 
and CPPC dummy-coded. 
OPPERA-S 
The OPPERA–Subset (OPPERA–S) cohort was a subset of the original OPPERA 
cohort that consists of 973 healthy controls that were not genotyped as part of the initial 
project as they were saved for further replication. Sleep was assessed using the PSQI and the 
same analytical plan was used as in the discovery cohort. DNA from all subjects was 
genotyped using the Axiom Precision Medicine Research Array. Genotyping data was 
cleaned and imputed in the same manner as the discovery cohort. Covariates included in the 
analysis included age, gender, dummy coded recruitment sites and 3 PCs. 
OPPERA-R 
The OPPERA-Replication (OPPERA–R) case-control study of chronic TMD (NIDCR 
protocol 12-052-E) was designed as a replication study from the initial OPPERA discovery 
GWAS. Recruitment was independent from the discovery cohort as it was done in 2016-
2017. Potential subjects were recruited by telephone screening of 166,062 phone numbers 































were eligible and 1,342 subjects (66% female, age 18-74) returned complete phenotype and 
genotype information and were included in the replication analysis. Phenotype was assessed 
using the question “please rate the quality of your sleep in the past three months on a 0-10 
scale” where 0 represented the worst sleep quality and 10 represented the best sleep quality. 
Saliva samples for DNA genotyping were obtained using Oragene collection tubes (DNA 
Genotek Inc., Kanata, Ontario). DNA from all subjects was genotyped using the Axiom 
Precision Medicine Research Array. Sleep scale scores were used as a dependent variable in a 
linear regression. Covariates included in the equation were age, gender, dummy coded 
recruitment sites and 3 PCs. 
Jackson Heart Study 
 The Jackson heart study (JHS) is a populational-based longitudinal prospective cohort 
aiming to investigate cardiovascular disease among African Americans (AA). Recruitment is 
community-based in the Jackson Mississippi metropolitan area. This study recruited 5,302 
AA adults between 2012 and 2016 [42].For this analysis, we used a subset of 2,999 
individuals that had both sleep assessment and genetic data. Sleep quality was determined at 
Exam 1 using the question “How do you rate your overall sleep quality?” with possible 
answers: Excellent, very good, good, fair, and poor. This cohort was genotyped using 
Affymetrix and imputed to a 1000 Genomes phase 1 version 3 template [43]. A univariate 
linear mixed model adjusted for genetic relatedness, age, and sex was used for each analysis 
using GEMMA version 0.94.1 [44]. 
Multi-Ethnic Study of Atherosclerosis 
The multi-ethnic study of atherosclerosis (MESA) is a multicenter prospective cohort 
study aiming to study the development of cardiovascular disease. A total of 6,814 individuals 
between the ages of 45 and 65 were recruited for the first examination between 2000 and 































County, NC; Los Angeles County, CA; Northern Manhattan, NY; and St. Paul, MN) [45]. In 
the present analysis, 518 participants from AA ancestry with complete data were used for 
replication (28%). Sleep quality was assessed using the question “In the past 4 weeks, rate the 
overall typical night of sleep”, extracted from the Center for Epidemiologic Studies 
Depression Scale (CES-D). Possible answers were: Very sound or restful, sound and restful, 
average quality, restless, very restless. This cohort was genotyped using the Affymetrix 6.0 
array, phased using SHAPEIT and imputed using IMPUTE2 with the Haplotype Reference 
Consortium version 1.1 template [46]. A univariate linear mixed model adjusted for genetic 
relatedness, age, and sex was used for each analysis using GEMMA version 0.94.1 [44]. 
Cleveland Family Study 
The Cleveland Family Study (CFS) aims to examine the genetic and familial basis of 
sleep apnea and consists of 2,534 African Americans and European Americans from 356 
families. Index probands with sleep apnea were recruited from northern Ohio sleep centers 
[47]. Sleep was assessed using the question “During the last month, have you had, or have 
you been told you do the following while asleep or trying to sleep? Toss, turn or thrash 
frequently over the night”. Values ranged from 0 (Never) to 4 (always or almost always, or 5-
7 times per week). A total of 719 African American individuals who had genotype data 
available and non-null values for the outcome variable were used for analysis. This cohort 
was genotyped using the Affymetrix 6.0 array, phased using SHAPEIT and imputed using 
IMPUTE2 with the Haplotype Reference Consortium version 1.1 template[46]. A univariate 
linear mixed model adjusted for genetic relatedness, age, and sex was used for each analysis 

































An additive model of inheritance was used to generate summary statistics for each 
replication cohort. The direction of phenotype scale in each cohort was reverted if necessary 
to be consistent across all cohorts included in the meta-analysis, i.e. higher score represents 
poor sleep. Next, genotypic effect statistics were corrected to reflect the effect of the same 
allele in each cohort. Because sleep was assessed differently in each of the replication 
cohorts, genotypic effects were standardized according to the method described elsewhere 
[48]. Briefly, if the phenotype was binary, the effect size was converted to a continuous 
standardized scale using the following formula: 




If the phenotype was continuous, the regression coefficient or the difference in mean 
generated was converted to a standardized effect size by dividing the effect size by the 
residual standard deviation [49].  
Meta-analysis of replication studies, excluding OPPERA discovery was computed 
using the R-package metafor using a fixed-effect method. The p-value shown is a two-sided 
p-value. Heterogeneity of effects was verified using the heterogeneity coefficient Q for each 
SNP. A race-specific meta-analysis was also computed to account for ethnicity. 
Drosophila Melanogaster assay  
Fly strain 
PDF-Gal4 has been previously described [50]. Varicose RNAi hairpins 1&2 (GD 
#24157, KK104548) was from the Vienna Drosophila RNAi Center VDRC. Flies were reared 
on a standard cornmeal–yeast–agar medium at 25°C and 70% relative humidity in a 12 hr 































5% sucrose). Flies were acclimated for at least 18 hr at 25°C in Light and Dark (LD) 
conditions, and then data were collected in LD for 7 days with the Drosophila Activity 
Monitoring (DAM) System (Trikinetics, Waltham, MA) in 5-min bins. Sleep parameters 
were measured by averaging 5 days of LD [51]. The sleep parameters tested were: circadian 
patterns of sleep, percentage of sleep, number of sleep episodes, and the duration of sleep 
episodes in minutes. These parameters were measured separately for L and D intervals. 
Group comparison was done between parental controls (PDF-Gal4/+, UASVariIR1-2/+) and 
varicose knockdown flies (DF-Gal4>UAS-variIR1-2). All statistical analysis was performed 
in Prism 7.0. Significance levels were determined by one-way ANOVA with Dunnett's 
multiple comparisons test. 
Results 
Genome-wide association study in OPPERA 
We first performed a primary discovery GWAS of sleep quality measured by the 
PSQI in the OPPERA cohort. The OPPERA cohort was comprised of self-declared non-
Hispanic whites (NHW, 58.4%), African Americans (AA, 25.8%), and other ethnic/racial 
groups including Asians, Pacific Islanders, Native Americans and individuals with mixed 
races (15.8%). Racial differences in sleep quality were observed in our data, with AA 
reporting lower sleep quality compared to NHW (Supplementary Table 1) which is consistent 
with previous reports [52]. 
Genome-wide analysis using the PSQI global score identified two loci on 
chromosomes 2 and 7 at genome-wide significance (P≤ 5x10
-8
), and one locus at suggestive 
significance (P≤ 5x10
-7
), on chromosome 13 (Table 1, Figure 1, Supplementary Figure 2, 
Supplementary Table 2). PSQI global score was associated with rs11976703 (effect allele C, 
β=0.78, standardized effect size=0.23, P=3.78x10
-8































standardized effect size=0.28, P=4.76x10
-8
) on chromosome 7 and rs60869707 (effect allele 
G, β=1.09, standardized effect size=0.32, P=5.03x10
-8
) on chromosome 2. The effect allele 
(the major allele) in each of these three SNPs was associated with higher global PSQI scores, 
hence worse sleep quality. Genome-wide significant SNPs were also analyzed for association 
with four PSQI subscales: subjective sleep quality, sleep efficiency, sleep disturbance, and 
daytime dysfunction. All SNPs showed the strongest association with subjective sleep quality 

































Table 1 Genome-wide (P ≤ 5x10
-8
) and suggestive (P ≤ 5x10
-7
) loci associated with PSQI in the OPPERA discovery 
cohort 
SNP Chr:position         
*Nearest 
genes 
EA/OA EAF INFO BETA SE P 






































































Chr: Chromosome; EA: Effect allele; OA: Other allele; EAF: Effect allele frequency; INFO: imputation quality from IMPUTE2. 

































The top SNPs on chromosome 7 were in linkage disequilibrium (D’=0.99; R
2
=0.83) 
in all populations, highest in Africans (D’=0.99; R
2
=0.95) and lowest in Europeans (D’=1; 
R
2
=0.15). The minor allelic frequencies for genome-wide significant SNPs were much higher 
in AA than in NHW (26% vs. 6% for rs11976703, 25% vs. 1% for rs73284230, and 23% vs. 
0.2% for rs60869707 in AA and NHW, respectively). In analyses stratified by self-declared 





; and rs60869707: β=1.04, P=6.17x10
-7
) but no effects in 
NHW (rs11976703: β=0.52; P =0.028; rs73284230: β=0.59; P =0.24; and rs60869707: 
β=0.99, P =0.99). A meta-analysis of ancestry specific results showed an association for 
rs11976703 (β=0.75, P=1.03x10
-6
; Q(2.56,P=0.11), Ihet=61), rs73284230 (β=0.92, P=2.6x10
-
6
; Q(0.35, P=0.55, Ihet=0) and rs60869707 (β=1.11, P=1.36x10
-7
; Q(0.06, P= 0.81, Ihet=0). 
Genome-wide analyses stratified by race did not show any SNP above genome-wide 
significance in NHW, whereas two loci on chromosomes 8 and 16 near TSNARE1 and 
FAM234A respectively, were significant in AA only (Supplementary Table 4 and 
Supplementary Figure 3). A sex-stratified analysis did not identify any significant SNPs in 
females, whereas in males rs28483449, on chromosome 15, located near ZNF710, was 
associated with PSQI (Supplementary Table 5). 
Heritability and pathway analysis of sleep quality 
Next, GWAS results were used to measure heritability of sleep quality. It was 
estimated at 14.37%, using GCTA [31], which was consistent with other heritability 
estimates of sleep traits [9]. Furthermore, pathway analysis of the full GWAS results using 
gene ontologies (GO) for “biological process” class function identified many significant 
biological pathways, of which more than half reflected different aspects of neuronal action 































the neuromuscular junction (Figure 2). These analyses are consistent with the current 
understanding of sleep processes, which largely depend on synaptic plasticity occurring 
during sleep, reinforcing the validity of results obtained from PSQI GWAS data [53]. 
Power analysis 
In order to assess if the discovery OPPERA cohort was powered to detect genome-
wide significant hits, we modeled the proportion of true hits given our sample size (2,868), 
the number of SNPs tested (1.83M), and three values of the standardized effect size (0.33, 
0.40 and 0.48). These values of effect sizes approximately correspond to the odds ratios 1.2, 
1.25, and 1.3 in a case-control design [48]. The model showed that among ten top-scoring 
SNPs, the expected false discovery rate (eFDR) [28] is high for the lowest standardized effect 
size (0.33) and reached only about 0.42 if the total number of tested SNPs carrying such 
effect size is 500. Thus, about six true positives were expected, i.e., (1-eFDR)*10 = 5.8. One 
would need about 200 true positive SNPs in the overall GWAS to bring eFDR below 0.05. 
However, larger standardized effect sizes (0.40 and 0.48) required smaller numbers of true 
positives. For example, about eight out of ten top-scoring SNPs are expected to be true 
positives (eFDR=0.153) for the standardized effect size equivalent to 0.48, assuming 100 true 
positive SNPs in total (Supplementary Figure 4). Hence, the discovery OPPERA cohort was 
well powered to detect true positives with the assumed effect sizes and densities in a GWAS 
using PSQI. 
Replication and meta-analysis 
To replicate our genome-wide significant associations, we used twelve independent 
cohorts that assessed sleep quality (Supplementary Table 6). The closest phenotype that 
captures sleep quality in the absence of PSQI was tested for association in each replication 































account for different measures of sleep (see Methods). The replication studies’ association 
results were then combined using a fixed-effect weighted meta-analysis for a total sample 
size of 100,805. Both rs11976703 and rs73284230 had a p-value < 0.05 in more than one 
individual replication study, whereas rs60869707 was only statistically significant in one 
replication cohort. In the overall meta-analysis, all three SNPs showed an effect size that is in 
the same direction as the discovery cohort, but only rs11976703 and rs73284230, on 
chromosome 7 replicated in a meta-analysis combining all replication studies (rs11976703: 
standardized effect [95%CI] =0.07 [0.02;0.12]; P=3.50 x10
-3
 and, rs73284230 standardized 
effect [95%CI] = 0.16 [0.08; 0.25]; P=2.0 x10
-4
































Table 2 Association of genome-wide significant SNPs in independent replication cohorts and meta-
analysis 




effect size (se) p-value 
rs11976703 OPPERA-Discovery 2,868 0.89 0.78 (0.14) 3.78 x10
-8
 
Effect allele (C) UKBB 79,947 0.95 -0.01 (0.03) 6.70 x10
-1
 
 HCHS/SOL 7,247 0.87 0.002 (0.013) 8.87 x10
-1
 
 Finnish BrePainGen* 800 0.95 0.12 (0.11) 3.54 x10
-1
 
 EA-CRASH 894 0.95 0.018 (0.10) 8.64 x10
-1
 
 CPPC 641 0.90 0.19 (0.09) 3.60 x10
-2
 
 OPPERA-S 929 0.87 0.14 (0.06) 3.20 x10
-2
 
 OPPERA-R 1,297 0.92 0.01 (0.07) 8.45 x10
-1
 
 AA-CRASH 906 0.70 0.27 (0.12) 2.10x10
-2
 
 PMPS 399 0.94 0.04(0.15) 7.87x10
-1
 
 JHS 2,999 0.73 0.03(0.03) 2.76x10
-1
 
 MESA 518 0.74 0.04(0.07) 5.99x10
-1
 
 CFS 719 0.74 0.02(0.06) 7.04x10
-1
 
 Meta-analysis 97,296  0.07 (0.03) 3.6 x10
-3
 
      
rs73284230 OPPERA-Discovery 2,868 0.92 0.95 (0.17) 4.76 x10
-8
 
Effect allele (G) UKBB 79,947 0.99 0.18 (0.08) 3.50 x10
-2
 
 HCHS/SOL 7,247 0.90 0.007 (0.014) 6.17 x10
-1
 
 EA-CRASH 895 0.99 0.29 (0.25) 2.52 x10
-1
 
 CPPC 657 0.93 0.16 (0.11) 1.50 x10
-1
 
 OPPERA-S 944 0.90 0.14 (0.07) 4.90 x10
-2
 
 OPPERA-R 1,328 0.96 -0.05 (0.10) 6.04 x10
-1
 
 AA-CRASH 915 0.71 0.23 (0.12) 7.80x10
-2
 
 PMPS 399 0.99 0.70 (0.32) 3.02x10
-2
 
 JHS 2,999 0.74 0.04(0.03) 2.16x10
-1
 
 MESA 518 0.75 0.04(0.07) 5.65x10
-1
 
 CFS 719 0.75 0.04(0.06) 5.25x10
-1
 
 Meta-analysis 96,568  0.16 (0.04) 2.0 x10
-4
 
      
rs60869707 OPPERA-Discovery 2,868 0.93 1.09 (0.20) 5.03 x10
-8
 
Effect allele (G) UKBB 79,947 0.99 -0.03 (0.15) 8.28 x10
-1
 
 HCHS/SOL 7,247 0.96 0.011 (0.025) 6.67 x10
-1
 
 EA-CRASH 896 0.99 0.39 (0.45) 3.88 x10
-1
 
 CPPC 622 0.94 0.08 (0.14) 5.98 x10
-1
 
 OPPERA-S 877 0.92 0.23 (0.10) 2.10 x10
-2
 
 OPPERA-R 1,282 0.97 -0.01 (0.15) 9.40 x10
-1
 
 AA-CRASH 915 0.76 -0.05 (0.15) 6.32x10
-1
 
 MESA 518 0.79 -0.01(0.08) 8.89x10
-1
 
 CFS 719 0.78 -0.04(0.07) 5.67x10
-1
 
 Meta-analysis 93,023  0.07 (0.06) 2.48 x10
-1
 
*All directions are presented with respect to the effect allele. SNPs rs73284230 and rs60869707 were not genotyped in the 
Finnish and rs60869707 was not genotyped in the PMPS and the JHS cohorts. The OPPERA Discovery cohort was excluded 
from the meta-analysis calculation. OPPERA: Orofacial Pain: Prospective Evaluation and Risk Assessment; UKBB: UK 
biobank; HCHS/SOL: Hispanic Community Health Study/Study of Latinos; EA: European American; AA: African 
American; PMPS: Post mastectomy pain syndrome. CPPC: Complex Persistent Pain Conditions. OPPERA-S: Subset; 
OPPERA-R: Replication; JHS: Jackson Heart Study; MESA: Multi-Ethnic Study of Atherosclerosis CFS: Cleveland Family 































In order to account for the large difference in allelic frequency between Europeans 
and African ancestries, we undertook a separate race-stratified meta-analysis in racially 
homogeneous cohorts. In Non-Hispanic whites ancestry only replication cohorts, both 
rs11976703 and rs73284230 replicated in the same direction as the discovery cohort 
(effect=0.07 and 0.16; P=0.047 and 2.0x10
-4
, respectively). The same was also true in 
African ancestry replication cohorts (effect=0.09 and 0.087; P=0.017 and 0.027, 
respectively). Overall, we concluded that both SNPs rs11976703 and rs73284230 have a 
significant effect on sleep quality in both ancestries (Supplementary Table 7). 
The following analyses will focus solely on the locus of chromosome 7 given that it is 
the only locus that replicated in an independent meta-analysis. 
Genetic analysis of locus chromosome 7 
 Using a probabilistic identification of causal SNP (PICS) approach, we determined 
that the probability for causality was distributed as 51.33% for rs11976703 and 26.53% for 
rs73284230. A conditional analysis showed that both SNPs are not independently associated 
with global PSQI score (rs73284230condit11976703; beta= 0.5147; P=6.9x10
-2
). The combined 
annotation-dependent depletion (CADD) scores for rs11976703 and rs73284230 were 0.19 
and 1.718, respectively, which does not indicate high deleteriousness [54].  
The locus on chromosome 7 is situated between neuropeptide Y (NPY) and membrane 
palmitoylated protein 6 (MPP6) genes with a surrounding LD structure that differs between 
ancestries (Figure 1a,b). Using EUR and AFR as reference panels, it can be observed that 
SNPs in high LD with rs11976703 are located in MPP6 (EUR), or upstream of it (AFR). All 
highly associated SNPs (P< 1x10
-4
) around rs11976703 were upstream of MPP6 and 
downstream of NPY. Nevertheless, the associated locus is substantially closer to the promoter 































SNP association with other phenotypes 
According to the Genome-wide Repository of Associations between SNPs and 
Phenotypes (GRASP) [55], rs11976703 was previously reported to be associated with 







 respectively [56-58]. By contrast, rs73284230 was not 
associated with any phenotype in GRASP.  
We next evaluated whether the effects of SNPs associated with sleep quality were 
mediated by phenotypes known to influence sleep quality and available in the OPPERA 
cohort. Six clinically relevant phenotypes were tested for correlation with the PSQI score: 
two clinical pain conditions (painful temporomandibular disorders (TMD) and low back 
pain), two measures of psychological distress (trait anxiety and depression), and two 
measures of sensitivity to experimental pain (heat pain tolerance and threshold). All six 
phenotypes correlated with PSQI. SNPs rs11976703, rs73284230, and rs60869707 were also 
associated with depression, anxiety and experimental pain (Supplementary Tables 8 and 9). 
After adjustment for each potential mediator individually, the allelic effect was slightly 
attenuated but remained statistically significant. After inclusion of all potential mediators 
simultaneously, the effect size for each genome-wide significant SNP was attenuated by 
around 45% but remained statistically significant (P< 0.05) (Supplementary Table 10), even 
after correcting for seven tests. Consequently, the effect of SNPs on sleep is unlikely to be 
fully mediated by pain states or psychological distress. 
Furthermore, using Genome-wide Complex Trait Analysis (GCTA), we calculated the 
genetic correlation (Rg) between PSQI and the above-mentioned phenotypes. We did not find 
evidence for genetic correlation of PSQI with TMD, back pain, anxiety and depression, 































correlation (heat pain threshold, Rg=0.68, P=0.09 and heat pain tolerance Rg=0.53, P=0.07) 
(Supplementary Table 11a). Furthermore, a LDHub [59] screen with 173 disease/traits from 
publicly available summary GWAS did not show any genetic correlations, with inflammatory 
bowel disease and Crohns disease showing nominal significance at P=0.05  (Supplementary 
Table 11b). This might be due to the fact that we were underpowered to detect any 
association. Because the findings are not sufficiently robust, we hesitate to draw firm 
conclusions.   
eQTL analysis 
The two SNPs on chromosome 7 that replicated in the meta-analysis were tested for 
evidence of functional effects through the expression quantitative trait loci (eQTL) analysis 
using BRAINEAC and Genotype-Tissue Expression (GTEx) databases in twelve brain 
tissues. At P=0.05, rs73284230 was not an eQTL in any brain tissues in any dataset. 
However, because of its low allelic frequency this analysis was underpowered. In 
BRAINEAC the effect allele (C) of rs11976703 was associated with lower mRNA levels of 
MPP6 in brain tissues averaged, with a p-value of 3.6x10
-4 [32]
. Furthermore, rs11976703 was 
an MPP6 eQTL in the GTEx dataset in the same direction in the frontal cortex with p-values 
of 9.56x10
-3 
(Supplementary Figure 5). Although this association P-value did not cross the 
strict Bonferroni correction for 12 tissues (P=4.2x10
-3
), substantial correlation of expression 
in GTEx brain tissues suggests employment of this threshold to be very conservative [33]. 
Additionally, some brain tissues are duplicates of each other in the GTEx dataset (for 
example, cortex and frontal cortex) [33]. Finally, in the GTEx dataset this same allele (C) of 
rs11976703 is also associated with lower mRNA levels of NPY in the anterior cingulate 
cortex, the cerebral hemisphere, the cerebellum and the frontal cortex with p-values ranging 
from 0.05 to 1.4x10
-4 































Functional Validation in vivo 
To investigate the functional role of genes on chromosome 7 in regulating sleep 
quality in vivo, we used the fruit fly Drosophila melanogaster [60]. In previous studies, NPF, 
the fly ortholog for NPY, has been implicated in suppression of sleep during starvation [61]; 
however, nothing is known about the role of Drosophila ortholog of MPP6 (varicose) in 
sleep. In the fruit fly, sleep quality is controlled by lateral ventral neurons (LNv) in the brain 
which can be specifically manipulated using the driver PDF-Gal4 [50]. Using transgenic 
RNAi (UAS-Inverted repeat; UAS-IR), we generated varicose knockdown flies specifically 
within LNv neurons (PDF-Gal4> UAS-vari
IR1/2
). Sleep patterns for these flies were then 
compared to parental controls (PDF-Gal4/+ or UAS-vari
IR1/2
/+). Firstly, we did not observe 
any difference in circadian behavior between parental controls and transgenic flies (Figure 
4a). Next, although no difference was observed in daytime sleep behavior, PDF-Gal4>UAS-
vari
IR1/2
 flies showed a marked reduction in overall nighttime sleep duration (Figure 4b) 
without a difference in sleep fragmentation assessed by the total number of sleep episodes 
(Figure 4c). Accordingly, we observed longer sleep episode duration in day time in PDF-
Gal4>UAS-vari
IR1/2 
animals (Figure 4d). Together, our results show reduced sleep time 
during the night and increased durations of sleep episodes during day in MPP6 RNAi flies 
which represents poor sleep homeostasis [62] and this may be a proxy for poor sleep quality. 
The poor sleep during the night appears to be compensated by longer sleep duration bouts 
during the day that can serve as consolidation. This effect supports the GWAS finding since 
the effect allele associated with worse sleep was an eQTL with lower mRNA levels of both 
MPP6 and NPY. Overall, we concluded that varicose (MPP6) expression plays a major role 

































In this study, a GWAS analysis revealed novel loci and genes associated with sleep 
quality, measured by the validated PSQI questionnaire. Overall, 15% of the variation in the 
global score of PSQI was explained by the combined additive effects of assessed SNPs. 
Previous twin studies showed that the PSQI global score is highly heritable (34-37%) [19,63]. 
In this study, the heritability estimate for PSQI global score was lower, commonly observed 
when comparing SNP-based heritability estimates with twin studies. However, the reported 
SNP-based heritability estimate was within the range of what was previously reported from 
GWAS for other sleep traits; i.e. 11.5% for insomnia disorder [64] and 10.3% for self-
reported sleep duration [9].  
The two loci reported here, on chromosomes 2 and 7, were not previously reported to 
be linked to any sleep phenotype in human association studies. ATOH8 has been implicated 
in the development of the nervous system and muscles but has not been reported to be related 
to sleep [65]. ATOH8 is a transcription factor that recognized an E-box element and regulates 
transcription of genes [66]. More than 9 circadian clock genes are E-box-regulated genes and 
occur in a rhythmic fashion [67]. Whether ATOH8 specifically binds a circadian clock gene is 
unknown, but our genetic association could open the door to new research avenues, though 
we recognize that this finding was not replicated in independent cohorts.  
The locus situated downstream of NPY and upstream of MPP6 was replicated in 
independent cohorts. The NPY gene codes for Neuropeptide Y, the most abundant peptide of 
the central nervous system and a master regulator of stress response, circadian and feeding 
rhythms through afferent projections from the hypothalamus [68,69]. Neuropeptide Y has 
been found to promote sleep in humans and zebrafish [70,71]. NPY was also identified as an 































Through a genetic screen in zebrafish, it was reported that the overexpression of NPY 
increases sleep by inhibiting noradrenergic signaling [71], while in the fly NPF integrates 
feeding and sleep behavior [61]. Importantly, no genetic association between NPY and sleep 
quality in humans has been reported previously.  
MPP6 codes for membrane palmitoylated protein 6, a member of the peripheral 
membrane-associated guanylate kinase (MAGUK) family. This family includes synaptic 
scaffolding proteins DLG1 and PSD95 [74], which have never been previously associated 
with any sleep related phenotype. In D. Melanogaster, this gene was previously shown to 
regulate the formation of the fly respiratory system [75] but has not yet been implicated in 
regulating sleep.  
Interestingly, the collective evidence suggests that the locus on chromosome 7 
identified in our study affect functions of two genes simultaneously, NPY and MPP6, where 
NPY is a known sleep gene and MPP6 is a novel sleep gene. This possibility would be in line 
with the relatively strong effect of the identified locus on sleep phenotypes. In tissue-
expression analysis, the effect allele of the top SNP was found to be associated with lower 
MPP6 and NPY expressions in many brain tissues, including the cerebral hemispheres, the 
anterior cingulate cortex, the cerebellum and the frontal cortex. The direction of association 
was consistent between brain tissues and validated in two independent datasets. Taking into 
account our genetic findings, where the effect allele was associated with higher PSQI global 
scores, hence worse sleep quality, our genetic results suggest that lower levels of MPP6 and 
NPY expression are associated with worse sleep, which is in agreement with what is known 
for NPY [68,71]. 
We then decided to take an additional step and test the functionality of MPP6 in vivo, 































sleep homeostasis (worse sleep) compared to parental controls. Although the behavioral 
translation between species is difficult to interpret, the direction of the effect is consistent. 
The association of MPP6 RNA with chromosome 7 locus can be a consequence of genetic 
co-regulation of these two genes resulting from the physical proximity in the human genome, 
but in D. Melanogaster these two genes are not situated at the same gene locus. Thus, our fly 
experiments reemphasize the independent functional role of the MPP6 gene in sleep.  
MPP6 acts centrally as the conditional knockdown was done in the sleep center 
neurons (LNv) of the fly brain. In humans, MPP6 is known to be expressed in the central 
nervous system; however, its function is still unknown. MPP6, previously named VAM-1, is 
expressed across the central nervous system, with highest expression in the cerebellum, the 
caudate and in the pituitary gland. Its sequence is predicted to contain a conserved PDZ 
domain that binds to veli-1. Veli-1 is a protein that helps couple synaptic vesicle exocytosis 
with neuronal cell adhesion, suggesting that it promotes the assembly of veli-1 containing 
protein complex in neurons [76]. Veli-1 also binds PDZ-motif containing proteins that are 
known to contribute to receptor clustering complexes at the post-synaptic levels [77]. 
 Our pathway analysis of the full GWAS revealed pathways that are in line with 
MPP6’s function. Pathways such as regulation of synaptic structural plasticity and receptor 
internalization point towards an important genetic contribution of processes occurring at the 
synaptic level and towards a role for receptor anchoring at the synapse. Many previously 
identified molecules such as neuroligin, neuropeptides, ion channels, vesicle proteins and 
scaffolding molecules have been shown to be regulated by sleep homeostasis and circadian 
rhythms [78]. Indirect evidence from our pathway analysis, the role of MPP6 in synaptic 
receptor clustering and ATOH8 as a transcription factor for clock genes, support this 
hypothesis. These findings open the door to future research that should focus on the role of 































well as sleep homeostasis using complementary methods such as electroencephalography in 
mouse models.   
In this study, in line with many other reports [4], we show that there is a significant 
relationship between the report of pain conditions, like TMD and back pain, with poor sleep 
quality. Moreover, we show that there is a positive correlation between psychological factors, 
like anxiety and depression, with poor sleep quality, as well as a positive correlation between 
experimental heat pain sensitivity and poor sleep. These epidemiological associations did not 
translate into genetic correlation findings in our study, probably due to modest size of a 
discovery cohort. On the other hand, based on publicly available data, our lead SNP was 
previously shown to be associated with cardiovascular disease and BMI. This finding is in 
line with poor sleep being a predisposing factor to poor cardiovascular health. The pathway 
by which NPY and MPP6 participate in the manifestation of cardiovascular disease remains 
unknown. Further work is needed to determine if variations in NPY and MPP6 are 
independent or show causal links between poor sleep quality and cardiovascular disease. 
This study presents some limitations that should be addressed. First, even though we 
demonstrated that we can identify true positives in our discovery cohort, we have to 
acknowledge that the sample size of our discovery cohort is small. A larger cohort would 
have more power to identify additional loci and stronger associations. Second, the phenotype 
that we used to assess sleep quality, the PSQI, is based on self-report although through a 
validated questionnaire and not on objective assessment of sleep with polysomnography. Our 
study’s phenotype is a compromise between the use of a self-reported unspecific question 
derived from a large dataset of hundreds of thousands of individuals and a smaller study with 
comprehensively assessed polysomnography but lacking power for a genome-wide analysis. 
In an ideal scenario, our results should be validated with more objective measures including 































chosen for replication were closer to insomnia than sleep quality. While the PSQI has a 
number of questions related to insomnia, it also has non-insomnia questions and has only 
modest correlations with insomnia questionnaires. The heterogeneity in the phenotypes might 
explain why replication was weaker in certain cohorts.  
In summary, we performed a discovery GWAS of sleep quality and identified two 
novel sleep loci. In a meta-analysis of twelve independent cohorts, we replicated the 
association with one locus on chromosome 7, situated between two genes, NPY and MPP6. 
Our eQTL analysis established the association of this locus in an allelic-dependent expression 
of both NPY and MPP6.  While NPY is thought to be important for sleep [68], MPP6 has not 
previously been implicated in regulation of sleep. Using sleep center-specific gene 
knockdown in the fly, we showed that decreasing levels of fly ortholog of MPP6 leads to 
altered sleep homeostasis (i.e. worse sleep) in vivo, establishing its functionality. Overall, 
these data are consistent with the observed allelic association between MPP6 and human 
sleep quality. Our results have broad biological significance by recognizing the role of MPP6 
as a novel sleep gene, potentially involved in synaptic processing in sleep centers. This work 
provides new insights into sleep biology and our findings should spur future investigation of 
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Figure captions list 
Figure 1: Regional association plots of discovery GWAS for PSQI global score in OPPERA 
(a-b) Regional association plots for genome-wide significant loci at chromosome 7 using 
EUR as a reference panel (a) and AFR panel (b). (c-d) Regional association plot at 
chromosome 2 using EUR as reference panel (c) and AFR panel (d). (e-f) Regional 
association plots for suggestive loci at chromosome 13 using EUR as reference panel (e) and 
AFR panel (f) Chromosomal position (Mb) is indicated on the x axis, and the –log10 p-value 
is indicated on the y axis. Each SNP is plotted as filled circle and the lead SNP is shown in 
purple. The genes within each region are shown in the lower panel. Recombination sites and 
rates are shown in blue. Additional SNPs in the locus are colored according to linkage 
disequilibrium (r2) with the lead SNP. rs78633772 instead of rs376585198 as the latter is not 
in the reference panel. 
Figure 2: Pathway analysis of sleep GWAS using Gene ontology’s biological process. 
Horizontal bar plots represent –log10 p-value enrichment of pathways. The red line 
represents Bonferroni threshold for statistical significance.   
Figure 3: Forest plots in meta-analysis. Forest plots of standardized effect size with 95% 
confidence interval for each replication study as well as for the fixed-effect meta-analysis for 
genome-wide significant SNPs. Higher effect sizes represent worse sleep quality. The 
discovery cohort was excluded from the meta-analysis calculation. The test of heterozygosity 
for each SNP was Q(df 11)=16.29 P=0.13 for rs11976703; Q(df 10)=20.52 P=0.03 for 
rs73284230 and Q(df 8)=6.74 P=0.57 for rs60869707. The sample sizes for the meta-analysis 
































Figure 4: LNv-specific knockdowns of Varicose in D. Melanogaster. PDF-Gal4 is a neuron-
specific driver. UAS-IR represents transgenic RNAi inverted repeats. PDF-Gal4/+, UAS-
VariIR1-2/+ are parental control flies. PDF-Gal4>UAS-variIR1-2 are varicose knockdown 
flies within LNv neurons.  (a) Circadian pattern of sleep (n=28-32). (b) Percentage of sleep in 
day time and night time (n=28- 32). (c) Number of sleep episode in day time and night time 
(n=28-32). (d) Sleep episode duration in minutes in day time and night time (n=28-32). Data 
presented as mean ± S.E.M. Statistics were determined one-way ANOVA with Tukey's 
multiple comparisons test. n.s., not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, and 
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